Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 7/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8074259 | 1.00 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603749 | 1.00 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL345882 | 0.94 | MTNR1A (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL345881 | 0.94 | MTNR1A (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603880 | 0.94 | MTNR1A (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL970670 | 0.88 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL10225789 | 0.87 | MTNR1A (0.51) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8066286 | 0.87 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL9361562 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8076235 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | claimed |
| US-4374148-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-02-15 | — | — | US | claimed |
| US-12565483-B2 | Oxopyrrolidine urea FPR2 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240109832-A1 | RAPID CONSTRUCTION OF TETRALIN, CHROMANE, AND INDANE MOTIFS VIA CYCLATIVE C-H/C-H COUPLING: FOUR-STEP TOTAL SYNTHESIS OF (±)-RUSSUJAPONOL F | NATIONAL INSTITUTES OF HEALTH | 2024-04-04 | — | — | US | disclosed |
| US-20230303513-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303513-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303513-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116568658-A | Rapid construction of tetrahydronaphthalenes, chromanes and indane motifs via cyclized C-H/C-H couplings | 斯克里普斯研究学院 | 2023-08-08 | — | — | CN | disclosed |
| EP-4196471-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-116057055-A | Oxo-pyrrolidine urea FPR2 agonists | 百时美施贵宝公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6310107-B1 | (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| US-5130339-A | Intestine and uterine motility modulators for reduction of intraocular pressure for glaucoma treatment | SANOFI (FR) | 1992-07-14 | — | — | US | disclosed |
| EP-0284359-B1 | 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| US-4530919-A | A 1,2,3,4-tetrahydronaphthalene carboxylic acid | PFIZER INC. (US) | 1985-07-23 | — | — | US | disclosed |
| US-4374148-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4305955-A | ORAL HYPOGLYCEMIC AGENTS, CHROMAN-4-CARBOXYLIC ACID OR THIOCHROMAN-4-CARBOXYLIC ACID | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303513-A1 | OXOPYRROLIDINE UREA FPR2 AGONISTS | FPR1, FPR2, FPR3 | CA1 4808/4885CA2 4020/4885ACHE 4625/4885 |
| US-12565483-B2 | Oxopyrrolidine urea FPR2 agonists | FPR1, FPR2, FPR3 | CA1 4259/4885CA2 2726/4885ACHE 4848/4885 |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | CA1 3139/4885CA2 3174/4885ACHE 1381/4885 |
| US-20240109832-A1 | RAPID CONSTRUCTION OF TETRALIN, CHROMANE, AND INDANE MOTIFS VIA CYCLATIVE C-H/C-H COUPLING: FOUR-STEP TOTAL SYNTHESIS OF (±)-RUSSUJAPONOL F | HCCS, TAC3, CTRC | CA1 1578/4885CA2 2470/4885ACHE 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.